{"entity":{"type":"insider","cik":"0001294517","url":"/insider/0001294517","json_url":"/insider/0001294517.json","name":"Hoenlein Malcolm","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":4,"first":"2005-04-26","last":"2020-09-01","span_basis":"filed_date"},"name_variants":[{"name":"Hoenlein Malcolm","source":"filing","n_filings":4,"first_seen":"2005-04-26","last_seen":"2020-09-01"}],"transactions":[{"id":3002685,"accession":"0001104659-20-101102","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-101102","line_url":"/filing/0001104659-20-101102#line-1","is_derivative":false,"issuer_cik":"0001294517","issuer_name":"Fortress Biotech, Inc.","issuer_ticker":"FBIO","issuer_name_source":null,"issuer_url":"/issuer/0001294517","owner_cik":"0001294517","owner_name":"Hoenlein Malcolm","owner_display_name":"Hoenlein Malcolm","owner_url":"/insider/0001294517","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"SERIES A CUMULATIVE PERPETUAL PREFERRED STOCK","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16667.0,"shares_display":"16,667","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":300006.0,"total_display":"300,006.00","total_whole":"300,006","shares_owned_after":16667.0,"shares_owned_after_display":"16,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-08-26","filed_date":"2020-09-01","scope":"insider"},{"id":6436236,"accession":"0001144204-14-066502","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-14-066502","line_url":"/filing/0001144204-14-066502#line-1","is_derivative":false,"issuer_cik":"0001294517","issuer_name":"CORONADO BIOSCIENCES INC","issuer_ticker":"CNDO","issuer_name_source":null,"issuer_url":"/issuer/0001294517","owner_cik":"0001294517","owner_name":"Hoenlein Malcolm","owner_display_name":"Hoenlein Malcolm","owner_url":"/insider/0001294517","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock, par value $0.001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25000.0,"shares_display":"25,000","price_per_share":1.61,"price_display":"1.61","price_state":"stated","total_value":40250.0,"total_display":"40,250.00","total_whole":"40,250","shares_owned_after":55000.0,"shares_owned_after_display":"55,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-06","filed_date":"2014-11-10","scope":"insider"},{"id":3800623,"accession":"0001144204-06-055133","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-06-055133","line_url":"/filing/0001144204-06-055133","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001294517","owner_name":"Hoenlein Malcolm","owner_display_name":"Hoenlein Malcolm","owner_url":"/insider/0001294517","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":13.231428571428571,"price_display":"13.23","price_state":"stated","total_value":92620.0,"total_display":"92,620.00","total_whole":"92,620","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-12-29","filed_date":"2006-12-29","scope":"insider","n_lines":2},{"id":1548702,"accession":"0001209191-05-022265","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-05-022265","line_url":"/filing/0001209191-05-022265#line-1","is_derivative":false,"issuer_cik":"0001114220","issuer_name":"KERYX BIOPHARMACEUTICALS INC","issuer_ticker":"KERX","issuer_name_source":null,"issuer_url":"/issuer/0001114220","owner_cik":"0001294517","owner_name":"Hoenlein Malcolm","owner_display_name":"Hoenlein Malcolm","owner_url":"/insider/0001294517","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":9.62,"price_display":"9.62","price_state":"stated","total_value":19240.0,"total_display":"19,240.00","total_whole":"19,240","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2001-02-02","filed_date":"2005-04-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":3,"open_market":true},{"code":"S","label":"Open-market sale","n":2,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001429260","name":"Fortress Biotech, Inc.","url":"/issuer/0001429260","role":"Director","n_filings":2,"first_seen":"2014-11-10","last_seen":"2020-09-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001114220","name":"KERYX BIOPHARMACEUTICALS INC","url":"/issuer/0001114220","role":"Director","n_filings":2,"first_seen":"2005-04-26","last_seen":"2006-12-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001294517","retrieved_at":"2026-08-23T11:08:01+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}